Abstract
The blood-brain barrier limits the therapeutic efficacy of systemic administration of anti-inflammatory and/or neuroprotective molecules to patients affected by immune-mediated inflammatory demyelinating diseases of the central nervous system (CNS) such as multiple sclerosis. Drug delivery to the CNS using non-replicative viral vectors may represent a valid alternative therapeutic strategy. Gene therapy for multiple sclerosis might include different human-grade' vectors, which could be used to deliver anti-inflammatory molecules as well as neuroprotective agents into the CNS in a flexible and useful way. These potential 'therapeutic' vectors would have different life spans, tissue tropism and infectivity rates.
| Original language | English |
|---|---|
| Pages (from-to) | 84-88 |
| Number of pages | 5 |
| Journal | International MS Journal |
| Volume | 10 |
| Issue number | 3 |
| Publication status | Published - Aug 2003 |
Keywords
- Blood-brain barrier
- Gene therapy
- Multiple sclerosis
- Vectors
ASJC Scopus subject areas
- Clinical Neurology